5 pharma stocks to watch out for on August 25

While the benchmark indices and broader market at large are trading in the green after 2 days of volatility, the Pharma sector is painted in red with Nifty Pharma quoting at 12,621.90 with a loss of 0.2%.

Lupin Ltd on August 24, post market hours announced that it has acquired brands Ondero and Ondero - Met (including trademark rights associated with the brands) by entering into a Deed of Assignment with Boehringer Ingelheim International GmbH The acquisition will enable the company to provide comprehensive and best-in-class treatment options for diabetes management. The consideration for the acquisition of these brands is Euro 26 million. At 11.30 am, the shares of Lupin are quoting at Rs 667.80, down by 1.5% or Rs 9.80 per share.

AstraZeneca Pharma India has received import and market permission in Form CT-20, the subsequent new drug approval, from the Drugs Controller General of India for Olaparib film-coated tablets. With this approval, Olaparib film-coated tablets of 100mg and 150mg can be indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. At 11.00 am shares of AstraZeneca Pharma were quoting at Rs 3057.55per share with a gain of 1.5% over its previous close.

Shilpa Medicare’s subsidiary Shilpa Biologicals (SBPL) has successfully completed the phase 3 human clinical studies of its first biosimilar, the 100mg/ml high concentration (HC) Adalimumab biosimilar. The company has submitted the dossier to the CDSCO for review and grant of marketing or manufacturing license - a first in India. The drug is expected to cater to diseases such as rheumatoid arthritis, plaque psoriasis, and Ulcerative Colitis. At 11.30 am shares of this pharma company were quoting at Rs 386.90 per share with a loss of 1.1% over its previous close.

Glenmark Pharmaceuticals - The US Food and Drug Administration (US FDA) has tagged the company’s Monroe, North Carolina (USA) facility as “Official Action Indicated” (OAI). The OAI classification implies inter‐alia that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. The drug regulator has made 17 observations at Glenmark Pharma’s Monreo plant. In the morning session, the shares of Glenmark Pharma were trading at Rs 382.25, a gain of 0.6% over its previous close.

Aurobindo Pharma Limited on August 24 announced that its wholly-owned subsidiary company, Eugia Pharma Specialties Limited, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Medroxyprogesterone Acetate Injectable Suspension. The usage of the said injection is indicated for females of reproductive potential to prevent pregnancy. In the morning session, the shares of Aurobindo Pharma are trading flat at Rs 561.60.